News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gilead Sciences, Inc. (GILD) Shareholders Decimate Plan To Tie CEO Compensation To Drug Access


5/8/2014 7:52:44 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Gilead Sciences Inc. shareholders thumped a proposal Wednesday that would have tied the compensation of CEO John Martin to patient access to the company's groundbreaking drugs. The plan captured only 2 percent of the vote of Foster City-based Gilead's (NASDAQ: GILD) roughly 1.5 billion outstanding shares. It asked Gilead's board to include non-financial measures based on patient access to the company's drugs in determining CEO compensation.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES